KalVista Pharmaceuticals Inc KALV R2K

Q: What is the current share price of KalVista Pharmaceuticals Inc (KALV)?

As of 2026-07-14 21:23 PDT, KalVista Pharmaceuticals Inc (KALV) trades at $27.00 on NGM. Its 52-week range is $27.00 to $27.00.

Q: What is the market capitalisation of KALV?

KalVista Pharmaceuticals Inc (KALV) has a market capitalisation of $1.44B on NGM.

Q: What is the P/E ratio of KALV?

KALV trades at a trailing price-to-earnings (P/E) ratio of -6.85. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -70.31.

Q: Is KALV a good stock to buy?

This page provides a data-driven analysis of KalVista Pharmaceuticals Inc (KALV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.kalvista.com

Company Profile ↓

$27.00

+0.00% 1Y

Mkt Cap$1.44B

P/E-6.85

P/B-70.31

52W High$27.00

52W Low$27.00

Book Value$-0.38

EPS (TTM)$-3.94

Company Overview

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Recent Developments

5-Year Trend Long-term compounding — profit CAGR -40.9%.

Growth & Price Performance

Compounded Profit Growth

5 Years:	-40.93%
1 Year:	-

Stock Price Performance

1 Year:	+0.00%
6 Months:	-
3 Months:	-
1 Month:	-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot

Price Performance

1Y+0.00%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Earnings shrank at -40.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-6.85

Industry PE

25.41

Forward P/E

15.82

PEG Ratio

Book Value

$-0.38

Price to Book

-70.31

P/S

12.56

EV/EBITDA

-10.38

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-40.93%

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-62.68%

ROE

ROA

-54.70%

Profit Margin

Op Margin

-57.37%

Gross Margin

51.07%

EPS (Latest Qtr)

$-0.43

EPS (TTM)

$-3.94

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

4.97

Current Ratio

5.17

Debt

$284.31M

Total Assets

$328.92M

Current Assets

$314.20M

Working Capital

$262.79M

Ownership

Promoter Holding

1.72%

Chg in Prom Hold

FII / Inst Holding

136.88%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.44B

Total Revenue (TTM)

$114.48M

EBITDA

$-138.45M

Free Cash Flow

$-153.84M

Operating Cash Flow

$-89.32M

Shares Outstanding

53.24M

Gross Margin

51.07%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	KALV KalVista Pharmaceuticals Inc R2K	27.00	-6.85	$1.44B	0.00%	-62.68%	-	-	-40.93%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Jan 2018	Apr 2018	Jul 2018	Oct 2018	Jan 2019	Apr 2019	Jul 2019	Oct 2019	Jan 2020	Apr 2020	Jul 2020	Oct 2020	Jan 2021	Jul 2021	Oct 2021	Jan 2022	Jul 2022	Oct 2022	Jan 2023	Jul 2023	Oct 2023	Jan 2024	Mar 2024	Jun 2024	Jul 2024	Sep 2024	Oct 2024	Jan 2025	Mar 2025	Apr 2025	Jun 2025	Jul 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	96.00K	1.13M	2.33M	4.84M	3.72M	5.59M	3.89M	2.93M	3.37M	3.92M	1.58M	3.82M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	1.43M	13.69M	40.86M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	590.00K	1.23M	3.09M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	836.00K	12.46M	37.77M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.94M	-	50.02M	-	59.84M	58.51M	61.22M
Operating Income	-2.40M	-4.03M	-8.12M	-	-5.45M	-5.94M	-4.35M	-	-7.01M	-4.89M	-6.66M	-	-9.56M	-9.29M	-12.72M	-	-14.44M	-12.78M	-12.66M	-19.52M	-23.60M	-26.68M	-26.32M	-25.88M	-26.95M	-29.09M	-29.75M	-33.15M	-	-	-44.22M	-43.48M	-	-42.94M	-49.71M	-50.02M	-	-59.01M	-46.05M	-23.44M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41.19M	-	-49.88M	-	-54.16M	-42.57M	-17.55M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.84M	-	2.94M	-	3.52M	4.76M	5.59M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-44.26M	-	-53.08M	-	-57.94M	-47.33M	-23.49M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.25M	-	-855.00K	-	2.16M	2.16M	0
Net Income	-2.38M	-3.30M	-7.64M	-4.20M	-4.93M	-4.99M	-5.23M	-657.00K	-5.03M	-3.30M	-3.96M	-8.53M	-7.34M	-5.90M	-9.29M	-6.58M	-10.81M	-10.43M	-10.05M	-16.11M	-19.65M	-22.47M	-23.04M	-22.26M	-21.30M	-25.32M	-27.65M	-29.03M	-43.10M	-40.34M	-40.44M	-39.08M	-	-48.51M	-51.84M	-52.23M	-57.60M	-60.10M	-49.48M	-23.49M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.66	-0.80	-0.92	-0.94	-0.90	-0.75	-0.74	-0.80	-0.84	-	-	-0.87	-0.84	-0.91	-0.92	-0.98	-	-	-1.12	-0.92	-0.43
R&D Expense	332.00K	2.93M	3.34M	-	3.48M	4.36M	4.55M	-	8.36M	7.88M	7.65M	-	9.69M	9.79M	11.23M	-	11.16M	9.15M	9.10M	13.67M	17.55M	19.74M	18.19M	18.08M	20.06M	19.31M	19.09M	22.52M	-	-	26.61M	18.68M	16.61M	12.59M	14.17M	-	-	15.16M	11.99M	12.42M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Revenue	-	-	-	-	2.13M	1.50M	8.39M	16.13M	12.69M	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	81.31M	95.09M	131.99M	182.98M
Operating Income	-5.22M	-11.68M	-8.09M	-21.04M	-15.18M	-22.34M	-18.70M	-29.82M	-40.53M	-57.92M	-81.31M	-95.09M	-131.99M	-182.98M
EBITDA	-	-	-	-	-	-	-	-	-	-	-80.75M	-94.37M	-125.83M	-173.33M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	0	5.79M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-82.34M	-92.91M	-126.64M	-180.05M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	0	0	3.39M
Net Income	-5.68M	-13.36M	-7.23M	-24.85M	-11.44M	-18.60M	-15.80M	-20.82M	-29.12M	-46.24M	-82.34M	-92.91M	-126.64M	-183.44M
Diluted EPS	-	-	-	-	-	-	-	-	-1.64	-2.42	-3.36	-3.33	-3.44	-3.69
R&D Expense	4.23M	8.29M	8.29M	16.20M	14.66M	12.67M	18.24M	35.02M	40.19M	41.29M	70.17M	80.28M	86.17M	71.71M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Apr 2014	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Dec 2025
Total Assets	-	-	-	6.64M	-	56.79M	24.75M	34.34M	61.39M	118.13M	92.53M	272.01M	203.88M	183.20M	235.40M	250.77M	335.38M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	172.33M	225.69M	241.69M	320.15M
Cash & Equivalents	8.24M	9.78M	481.00K	3.90M	2.53M	53.72M	21.76M	30.95M	51.05M	32.01M	15.79M	50.59M	30.73M	56.24M	31.79M	131.62M	229.34M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3.43M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2.59M
Total Liabilities	-	-	-	11.27M	-	7.48M	-	-	-	-	-	-	-	22.18M	28.82M	155.38M	338.09M
Current Liabilities	-	-	-	7.09M	-	4.27M	3.25M	3.02M	23.22M	18.05M	7.72M	9.77M	11.58M	15.03M	22.81M	45.17M	57.35M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	139.23M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	8.23M	7.32M	6.31M	151.57M
Total Equity	-28.29M	-33.71M	-16.21M	-44.18M	-23.55M	49.31M	-37.11M	31.33M	27.25M	96.74M	83.75M	257.19M	185.09M	161.03M	206.58M	95.39M	-2.71M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	34.17M	42.52M	49.76M	50.90M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Operating Cash Flow	-	-	-	-	-13.16M	-23.72M	10.56M	-36.37M	-44.82M	-30.17M	-78.13M	-75.26M	-89.23M	-152.91M
Investing Cash Flow	-	-	-	-	-11.00K	34.06M	-1.43M	-69.42M	16.75M	-147.65M	57.86M	41.41M	-84.72M	91.02M
Financing Cash Flow	-	-	-	-	33.00M	2.00K	8.99M	87.94M	11.58M	212.12M	1.58M	58.12M	150.71M	159.73M
Capital Expenditure	-18.00K	-159.00K	-125.00K	-659.00K	-11.00K	-74.00K	-1.43M	-1.08M	-220.00K	-82.00K	-931.00K	-1.20M	-443.00K	-929.00K
Free Cash Flow	-	-	-	-	-13.17M	-23.80M	9.13M	-37.45M	-45.04M	-30.25M	-79.06M	-76.46M	-89.67M	-153.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-18.69M	24.27M	-23.24M	97.84M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-711.7%	-1,485.3%	-222.8%	-184.9%	-319.4%	-	-	-	-	-
Net Margin %	-	-	-	-	-536.1%	-1,236.9%	-188.3%	-129.1%	-229.4%	-	-	-	-	-
ROE %	16.8%	30.2%	30.7%	-50.4%	30.8%	-59.4%	-58.0%	-21.5%	-34.8%	-18.0%	-44.5%	-57.7%	-61.3%	-192.3%
ROCE %	-	2,600.7%	-	-40.1%	-70.6%	-71.3%	-49.0%	-29.8%	-47.8%	-22.1%	-42.3%	-56.5%	-62.1%	-89.0%

Shareholding Pattern

Insiders

1.72%

Institutions

136.88%

Public Float

139.27%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Venrock Adviser, LLC	12.16%	6.47M	$174.81M
2	Frazier Life Sciences Management, L.P.	9.32%	4.96M	$133.95M
3	Suvretta Capital Management, LLC	8.96%	4.77M	$128.76M
4	Tang Capital Management, LLC	8.59%	4.57M	$123.49M
5	Blackrock Inc.	7.13%	3.80M	$102.49M
6	SilverArc Capital Management, LLC	5.40%	2.88M	$77.66M
7	Capital World Investors	5.28%	2.81M	$75.83M
8	Point72 Asset Management, L.P.	4.01%	2.14M	$57.70M
9	State Street Corporation	3.67%	1.96M	$52.81M
10	Millennium Management Llc	3.59%	1.91M	$51.63M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KALV

Google News Wed, 29 Apr 2026

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOYXNkR0dRNWJRQkY0V3p4OUttQk0wa19rcmY2c3E2STlBeTFUYmpDeVg1WkRaVlpiY1o4SGt0MjlZSk93VTYzdTVtV21kZy1PQ1J3RlpFbWRDZ0pUMnpIZWF0emtpVnd1S0JpZGt0dG1UbjZ4TENjZmVrS2RsU2JISklIMzdrdE9veElUaH…

Google News Wed, 29 Apr 2026

$KALV stock is up 38% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQdjBPVHdrcTRHc2dIdWFmYTc4am1FLXBsYXJuNEtmMDhuVUpiZG9ublExeGxHak16RWc3dkFwcVA4dHpVY2xqZXYwWW5iOVVzQ19PemJQdHJYTjJoa0dSUEU3cS1Yb3N3R0JGNEVsZi1yOHc3X3piRU1XUjF6Z1RIMnZLOHozN2RMNER5bX…

Google News Sun, 31 May 2026

KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000 - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNeEZpdWJSUXRtajhKNmVSaWN3MEliZUxTYUhpTWltN3c3YkIyQXlDYlF2Q3RDb2lIQ0JwTk03cnU1YjJzSUdDNTJoblkyc0dvX0t5SzVDQ18tQ3RwVi1pZjlsTEtmYlNGQS1scFU0SEZ4ZXlpQVZqc3RyeE4zdWRCM3FCT1YzSk5tZDhyZE…

Google News hu, 11 Jun 2026

KalVista (KALV) acquired by Chiesi for $27.00 per share, deal closes - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNSUJsZTBmYUItWGRYTDRxcWJXOTR1VVZNaWxNcVYxMkFYR2tfVUFsWVd5LUNjZFJ0RWVUUEtxNWpqNjJaczlIUDc5NFF2d1JiVGlwR0l6M19KQmVOb2xxUnlXeVlvdjUxVGt3NmdmSS1lWjFsMXYwTVMxM05LRjBhQm51dld5dHFWUTBpZk…

Google News Wed, 11 Mar 2026

KalVista Stock Pre-Market (-0.2%): CEO Stock Sale for Tax Purposes Reported in SEC Filing - Trefis

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOY0J5cTFxRnVwaVJ5anlIcnU3T1FJS2J4a1RwRDNLLUVCeWRXdTlLOU05V20xVDlsOG9TTjJsZGZYekFqMlpjMWJQTVVUZmZsZGo0eFlDQ3U2MlRkZXA3OEw2aHhMVVpQV3dWMEo3Uzd6dGctcGJsR0xTMmYwckstMFBPTWxTODljZ214UH…

Google News ue, 19 May 2026

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Business Wire

<a href="https://news.google.com/rss/articles/CBMivAJBVV95cUxPLTl1OGtIN2FPVW82STBTcFliMzZ3QVRLRkhFMmVkUXM3aUpZTExOSWRjN2VpZC05RUMxcnJ2LWhraEZQQUVsN3hKamtERklSSWIxTmMzSlduWmZkNmVnNXBEeWo1bGFRSlpiWDk3TmV5eWotdHNmX2t0aUJZMENiZVloWXRlaW1nalM2VW…

KALV — Frequently Asked Questions

What is the current share price of KalVista Pharmaceuticals Inc (KALV)?

As of 2026-07-14 21:23 PDT, KalVista Pharmaceuticals Inc (KALV) trades at $27.00 on NGM. Its 52-week range is $27.00 to $27.00.

What is the market capitalisation of KALV?

KalVista Pharmaceuticals Inc (KALV) has a market capitalisation of $1.44B on NGM.

What is the P/E ratio of KALV?

KALV trades at a trailing price-to-earnings (P/E) ratio of -6.85. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -70.31.

Is KALV a good stock to buy?

This page provides a data-driven analysis of KalVista Pharmaceuticals Inc (KALV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

KalVista Pharmaceuticals Inc KALV R2K

Company Overview

Recent Developments

Growth & Price Performance

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - Yahoo Finance

$KALV stock is up 38% today. Here's what we see in our data. - Quiver Quantitative

KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000 - The Motley Fool

KalVista (KALV) acquired by Chiesi for $27.00 per share, deal closes - Stock Titan

KalVista Stock Pre-Market (-0.2%): CEO Stock Sale for Tax Purposes Reported in SEC Filing - Trefis

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV - Business Wire

KALV — Frequently Asked Questions

What is the current share price of KalVista Pharmaceuticals Inc (KALV)?

What is the market capitalisation of KALV?

What is the P/E ratio of KALV?

Is KALV a good stock to buy?

Explore More